Towards identification of true cancer biomarkers

BMC Medicine

Eleftherios P Diamandis¹ 

[1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

关键词: Mass spectrometry;    Selected reaction monitoring;    High specificity;    Mutant proteins;    Proteomics;    Genomics;    Cancer biomarker;   

Others  :  1121461
DOI  :  10.1186/s12916-014-0156-8

 received in 2014-07-14, accepted in 2014-08-19,  发布年份 2014

【 摘 要 】

Background

Most of newly discovered cancer biomarkers fail in the clinic because they lack sensitivity and/or specificity. The current explosion in knowledge of the mutational spectrum of many cancer types, as a result of whole exome and whole genome sequencing, has revealed a wide spectrum of mutations that appear to be highly specific for various cancer types.

Discussion

Mass spectrometry (MS) has the ability to monitor tryptic peptides in complex biological mixtures with high sensitivity and specificity. It may be possible in the near future to combine the known spectrum of gene mutations revealed by genomics with the power of MS, in order to quantify mutant peptides that are highly specific for cancer, in a multiplex fashion. Such mutant peptides, quantified in the circulation and other fluids, may represent tumor markers that are suitable for detection and monitoring of cancer.

Summary

The power of genomic and proteomic technologies can be combined to identify highly specific analytes for biomarker applications.

【 授权许可】

   
2014 Diamandis; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Diamandis EP, Hoffman BR, Sturgeon CM: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for the use of tumor markers. Clin Chem 2008, 54:1935-1939.
• [2]Kulasingam V, Pavlou MP, Diamandis EP: Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010, 10:371-378.
• [3]Diamandis EP: Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010, 102:1462-1467.
• [4]Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004, 96:353-356.
• [5]Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C: Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012, 4:127.
• [6]McCluggage WG: Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43:420-432.
• [7]Integrated genomic analyses of ovarian carcinoma Nature 2011, 474:609-615.
• [8]Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES, Getz G: Discovery and saturation analysis of cancer genes across 21 tumour types.Nature 2014, 505:495–501.
• [9]Diamandis EP: A repository for "rare" tumor markers?Clin Chem Lab Med 2014, [Epub ahead of print]
• [10]Buchen L: Cancer: Missing the mark. Nature 2011, 471:428-432.
• [11]Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L: Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
• [12]Ashworth A, Hudson TJ: Genomics: Comparisons across cancers. Nature 2013, 502:306-307.
• [13]Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IM, Kurman R, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman JR, Carvalho JP, Marie SK, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA Jr: Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013, 5:167ra4.
• [14]Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B: Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 2011, 108:9530-9535.
• [15]Deutsch EW, Lam H, Aebersold R: PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows.EMBO reports 2008, 9:429–434.
• [16]Craig R, Cortens JP, Beavis RC: Open source system for analyzing, validating, and storing protein identification data.J Proteome Res 2004, 3:1234–1242.
• [17]Surinova S, Hüttenhain R, Chang CY, Espona L, Vitek O, Aebersold R: Automated selected reaction monitoring data analysis workflow for large-scale targeted proteomic studies. Nat Protoc 2013, 8:1602-1619.
• [18]Drabovich AP, Dimitromanolakis A, Saraon P, Soosaipillai A, Batruch I, Mullen B, Jarvi K, Diamandis EP: Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. Sci Transl Med 2013, 5:212ra160.
• [19]Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW: SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 2009, 8:995-1005.
• [20]Niederkofler EE, Phillips DA, Krastins B, Kulasingam V, Kiernan UA, Tubbs KA, Peterman SM, Prakash A, Diamandis EP, Lopez MF, Nedelkov D: Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One 2013, 8:e81125.
• [21]Kulasingam V, Smith CR, Batruch I, Buckler A, Jeffery DA, Diamandis EP: "Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J Proteome Res 2008, 7:640-647.
• [22]Kulasingam V, Smith CR, Batruch I, Diamandis EP: Immuno-mass spectrometry: quantification of low-abundance proteins in biological fluids. Methods Mol Biol 2011, 728:207-218.
• [23]Shi T, Fillmore TL, Sun X, Zhao R, Schepmoes AA, Hossain M, Xie F, Wu S, Kim JS, Jones N, Moore RJ, Pasa-Tolić L, Kagan J, Rodland KD, Liu T, Tang K, Camp DG 2nd, Smith RD, Qian WJ: Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc Natl Acad Sci U S A 2012, 109:15395-15400.